Clinical Trials on Small Round-cell Sarcomas in Czechia

Total 166 results

University Hospital Ostrava

Recruiting

SBRT/RT in Oligometastatic Stage IV NSCLC

Non Small Cell Lung Cancer

Czechia
University Hospital Ostrava

Recruiting

Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Czechia
The Institute of Molecular and Translational Medicine...

Completed

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

Non Small Cell Lung Cancer | Circulating Tumor Cell

Czechia
Rhizen Pharmaceuticals SA

Completed

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Solid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal Cancer

Czechia, Poland
Eisai Inc.
Quintiles, Inc.

Completed

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Ukraine, Germany, United States, Italy, Czechia
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04)

Non-small Cell Lung Cancer Metastatic

Korea, Republic of, United States, Bulgaria, Czechia, Portugal, Spain
AstraZeneca

Completed

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Lung Cancer | Non Small Cell Lung Cancer

Bulgaria, Romania, Ukraine, France, Czech Republic
Novartis Pharmaceuticals

Terminated

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Non-small Cell Lung Cancer

France, Spain, United States, Belgium, Netherlands, Canada, Italy, Singapore, Korea, Republic of, Czechia, Germany, Hong Kong
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
AstraZeneca

Active, not recruiting

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Extensive-stage Small Cell Lung Cancer

Canada, Germany, Italy, Czechia, Turkey, Bulgaria
Astellas Pharma Inc

Completed

LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy

Lung Cancer | Carcinoma, Non-Small Cell Lung | Cancer of Lung | Non-Small Cell Lung Carcinoma | Cancer of the Lung

Germany, Czech Republic, Netherlands
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Genzyme, a Sanofi Company
Sanofi

Completed

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Neuroblastoma | Brain Tumors | Ewing's Sarcoma/Soft Tissue Sarcoma

Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Vaxon Biotech

Completed

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Non-small Cell Lung Cancer Metastatic

Germany, Greece, Spain, Romania, France, Italy, Czechia, Poland
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Non-small Cell Lung Cancer

United States, Czechia, India, Brazil, Argentina, Hungary
Threshold Pharmaceuticals
EMD Serono

Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Germany, Spain, Poland, Greece, Czechia, Hungary, Italy, Romania, Russian Federation
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Non-small-cell Lung Carcinoma | Lung Carcinomas, Non-Small-Cell

Spain, Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan, Lebanon, Malaysia, Mexico, Philippines, Poland, Romania, Russian Federation, Taiwan, Thailand, Turkey, Ukraine
Pfizer

Completed

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Adenocarcinoma | Non-Small-Cell Lung Carcinoma

United States, Spain, Poland, Czech Republic, United Kingdom, France
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
Biocad

Recruiting

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (DOMAJOR)

Non-Squamous Non-Small Cell Neoplasm of Lung

Czechia, Romania, Georgia, Hungary, Russian Federation, Slovakia
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
NovoCure Ltd.

Unknown

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)

1-5 Brain Metastases From Non-Small Cell Lung Cancer

Poland, Czech Republic, Italy, France, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
OSE Immunotherapeutics

Terminated

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (ATALANTE-1)

Non Small Cell Lung Cancer

France, Spain, Israel, United States, United Kingdom, Italy, Poland, Czechia, Germany, Hungary
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Shanghai Henlius Biotech

Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

United States, China, Greece, Spain, Austria, Czechia, Germany, Hungary, Latvia, Netherlands, Poland
AbbVie (prior sponsor, Abbott)

Completed

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-Small-Cell Lung Cancer

United States, Czech Republic, Greece, Hungary, Netherlands, Slovakia
GlaxoSmithKline

Completed

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome (SCOT)

Lung Cancer, Small Cell

Spain, France, Netherlands, Korea, Republic of, Greece, Slovenia, Italy, Czech Republic, Germany, Austria, Hungary, Poland, Estonia, Lithuania
Daiichi Sankyo, Inc.
Parexel

Terminated

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Lung Cancer | Non-small Cell Lung Cancer

United States, Italy, Poland, United Kingdom, Belgium, Spain, Canada, Germany, Czechia, Hungary
Eisai Inc.

Completed

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, United States, United Kingdom, Australia, Israel, Russian Federation, Czech Republic, France, Greece, Hungary, Poland
Xcovery Holdings, Inc.

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Hong Kong, United Kingdom, Poland, Israel, Germany, France, Argentina, Australia, Brazil, Canada, Czechia, Italy, Netherlands, Russian Federation, Turkey, Belgium
PharmaMar

Completed

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (ATLANTIS)

Small-cell Lung Cancer

France, United States, Germany, Spain, Belgium, Lebanon, United Kingdom, Italy, Netherlands, Brazil, Portugal, Greece, Argentina, Austria, Bulgaria, Canada, Czechia, Hungary, Poland, Romania
Gemin X
Cephalon

Completed

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Extensive-stage Small Cell Lung Cancer

Canada, United States, United Kingdom, Serbia, Bulgaria, India, Hungary, Czech Republic, Poland, Romania
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
AstraZeneca

Completed

Phase II Iressa Versus Vinorelbine (INVITE)

Non-Small-Cell Lung Carcinoma

Czech Republic, Italy, Korea, Republic of, South Africa, United Kingdom, Germany, Australia, Taiwan, France, Brazil
Genentech, Inc.

Completed

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Non-Squamous Non-Small Cell Lung Cancer

Australia, United States, Hungary, France, Germany, Czech Republic, Poland

Clinical Trials on Small Round-cell Sarcomas in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations